Multi-omics profiling of paired primary and recurrent glioblastoma patient tissues
Despite maximal therapy with surgery, chemotherapy and radiotherapy, glioblastoma multiforme (GBM) patients have a median survival of only 15 months. Almost all patients inevitably experience symptomatic tumor recurrence. A hallmark of this tumor type is the large heterogeneity between patients and within tumors itself which relate to failure of standardized tumor treatment. In this study, tissue samples of paired primary and recurrent GBM tumors were investigated to identify individual factors related to tumor progression.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
|AB GeneChip Scanner 3000 7G System Clariom S
Multiomics profiling of paired primary and recurrent glioblastoma patient tissues.
Neurooncol Adv 2: 2020 vdaa083